Teva (TEVA), Par Pharma (PRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical (Nasdaq: TEVA), Par Pharma (NYSE: PRX) said to lose bid to sell the generic form of Glaxo's (NYSE: GSK) Lovaza.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Is the global equity rally broadening? UBS weighs in
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, General NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
